INTRODUCTION AND OBJECTIVES: Therapeutic drug monitoring (TDM) has been recognized as a useful tool for optimizing the dosages of many drugs, even in molecular-targeted therapeutics. In this study, we examined the associations between the pharmacokinetics of sunitinib (SU) and its metabolite N-desethyl-sunitinib (DSU) and adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC).
INTRODUCTION AND OBJECTIVES: Therapeutic drug monitoring (TDM) has been recognized as a useful tool for optimizing the dosages of many drugs, even in molecular-targeted therapeutics. In this study, we examined the associations between the pharmacokinetics of sunitinib (SU) and its metabolite N-desethyl-sunitinib (DSU) and adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC).
METHODS: The pharmacokinetics of SU and DSU were examined in 26 patients (20 male and 6 female patients) with mRCC. Plasma SU and DSU levels were measured using high-performance liquid chromatography, and a pharmacokinetic study was performed on day 7 in the first cycle of SU. The associations between SU/DSU pharmacokinetics and the occurrence of AEs, best response rate, progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS) were investigated.
RESULTS: All patients were treated with 37.5 mg/day SU at the day of pharmacokinetics. The mean trough levels of SU and DSU were 76.7 and 16.8 ng/mL respectively. Occurrence of hand-foot syndrome and thrombocytopenia (P ¼ 0.002 and 0.024 respectively by MannWhitney test) was associated with high trough levels of SU. Low trough levels of DSU were significantly associated with drug discontinuation due to disease progression and were associated with worse tumor response (P ¼ 0.035 and 0.042 respectively by Mann-Whitney test, Figure 1 ). Patients with DSU trough levels of or higher than 15.0 ng/mL showed a tendency toward increased PFS, TTF, and OS than those with trough levels lower than 15.0 ng/mL (Figure 2 ). SU trough levels were not associated with prognosis.
CONCLUSIONS: TDM of SU and DSU in patients with mRCC may be useful to determine adequate dosages and prevent severe AEs. Further studies are required to establish the usefulness of TDM of SU and DSU for ensuring long-term clinical efficacy in patients with mRCC.
Source of Funding: none

MP16-02 INFLUENCE OF GENETIC POLYMORPHISMS ON THE PHARMACOKINETICS OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Kazuyuki Numakura*, Nobuhiro Fujiyama, Makoto Takahashi, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Takenori Niioka, Masatomo Miura, Tomonori Habuchi, Akita, Japan INTRODUCTION AND OBJECTIVES: Sunitinib (SU) is an oral multi-targeted tyrosine kinase inhibitor (TKI) for renal cell carcinoma (RCC). Because of severe adverse events (AEs) associated with its use, patients have to either reduce the dose or cease taking SU. Singlenucleotide polymorphisms (SNPs) from the ABCB1, ABCG2, CYP3A4, and CYP3A5 genes were reported to have an effect on individual pharmacokinetic variation in oral bioavailability of other TKIs. The aim of this study was to determine whether there exists an association between these SNPs with individual variation in sunitinib plasma concentration.
METHODS: From April 2006 to July 2015, we administrated SU to 80 metastatic RCC (mRCC) patients at Akita University. Of these patients, the pharmacokinetics of SU and its metabolite, N-desethyl sunitinib (DSU), were examined in 25 cases (19 males and 6 females). Plasma SU and DSU levels were measured using highperformance liquid chromatography, and a pharmacokinetic study was performed on day 7 of the first cycle. We tested for association between SU and DSU pharmacokinetics with SNP genotype and allele frequencies.
RESULTS: All patients were treated with 37.5 mg/day of SU on the day of pharmacokinetic assessment, and had mean trough levels of 76.7 ng/mL and 16.8 ng/mL for SU and DSU, respectively. The ABCB1 1236 TT genotype was associated with high SU trough levels compared to that found in patients with a #T or ## genotype (95.9 ng/mL versus 61.6 ng/mL, respectively; P ¼ 0.030). In addition, the ABCB1 2677 G allele was associated with high DSU trough levels compared to that seen with the 2677 # allele (12.7 ng/mL versus 18.8 ng/mL, respectively; P ¼ 0.047) ( Table 1) .
CONCLUSIONS: Our study found that the ABCB1 1236 TT genotype and the 2677 G allele were associated with increased trough levels of SU and DSU, respectively. Based on our findings, the pharmacokinetics of SU and DSU may be informative indicators to Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e179
